Novartis announced that its acute heart failure drug serelaxin failed to clear the last stage clinical trials. Following this announcement, Novartis shares dropped by 2.2 percent.
Novartis announced that its acute heart failure drug serelaxin failed to clear the last stage clinical trials. Following this announcement, Novartis shares dropped by 2.2 percent.
Share this Article
Recommended